Drug intelligence / Profile preview

PMB298

Development stage: Preclinical
Lead developer: PiMedBio
Modality: Small Molecules

Overview

PMB298 is a preclinical-stage bispecific small molecule (BSM) being developed by PiMedBio for the treatment of various cancers. It is designed to simultaneously target an undisclosed immune checkpoint suppressor and an undisclosed generator of the immunosuppressive tumor microenvironment (TME). By addressing both the direct inhibition of immune cells and the broader immunosuppressive environment within the tumor, PMB298 aims to enhance the anti-tumor immune response. The drug is currently in the candidate discovery stage of development and represents an application of PiMedBio's proprietary BSM platform technology.

Beyond the preview

Go deeper on PMB298.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMB298.

Explore the full profile